Spire Global: Still A Buyer Despite Recent Challenges
Spire Global stock dropped 50%, but with positive cash flow, new leadership, and growth prospects, shares under $9 could rise ...
Allarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027Strengthened cash position expected to support ...